Patient P-01389
Therapy response
Stable
Tolerance
Stable
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Unstable
Discontinuation risk
65%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 46 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 46 SC-12 recommended — Supportive Compound SC-12
- Day 47 Patient accepted — Started SC-12 in the companion
- Day 50 GI-04 recommended — GI Support Protocol GI-04
- Day 51 Patient accepted — Started GI-04 in the companion
- Day 53 GI symptom burden −18% vs expected — Supportive Compound SC-12
- Day 59 No meaningful change — GI Support Protocol GI-04
- Day 59 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 46.
Primary contributors, last 14 days
- GI instability-16
- Inflammatory activity-16
- Treatment adherence+12
- Nutritional resilience+3
What helped?
- Supportive Compound SC-12Day 46Result: symptom burden −18%
- GI Support Protocol GI-04Day 50Result: no meaningful change
LIFE OS recommendation
Dietary Support Protocol NP-02
53%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 66% showed improvement
- median effect visible after 10 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 48 and rising
- WearableSleep 4.4 h, below personal baseline
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 42/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↑65
- WearableResting HR 77 bpm
- Wearable549 steps/day
- WearableShort sleep window
- Inflammatory signalling ↓45
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 45
- Drug metabolism and exposure ↑20
- BloodToxicity index 49
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 2.6 · butyrate capacity 42/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 55 ms
- Sleep
- 5.3 h
- Steps
- 1,170
- Resting HR
- 79 bpm
Daily log: GI score 48, nutritional resilience 40, adherence 51.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01413 | 65% | S14 | GI-04 | improved | 44 |
| P-01356 | 60% | S14 | GI-04 | improved | 42 |
| P-01365 | 55% | S14 | SC-12 | improved | 49 |
| P-01598 | 54% | S14 | GI-04 | no change | 45 |
| P-01781 | 54% | S14 | NP-02 | improved | 45 |
| P-01436 | 51% | S14 | GI-04 | improved | 38 |
| P-01559 | 51% | S06 | GI-04 | improved | 42 |
| P-01831 | 51% | S15 | SC-12 | improved | 49 |
| P-01505 | 50% | S14 | NP-02 | improved | 41 |
| P-01707 | 50% | S14 | GI-04 | improved | 57 |
| P-01307 | 49% | S14 | GI-04 | improved | 43 |
| P-01438 | 49% | S14 | GI-04 | improved | 56 |